Stock Price Forecast

Nov. 3, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Histogen Inc chart...

About the Company

a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human extracellular matrix (ecm) material, exceltrix.

CEO

Steven Mento

Exchange

OTC MARKETS

Website

https://www.conatuspharma.com/

$3M

Total Revenue

25

Employees

$1M

Market Capitalization

-0.10

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $HSTO News

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

7d ago, source:

Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further ...

Histogen Inc HSTO

1mon ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Inflation, Rate Hikes And JPMorgan Earnings: Forbes AI Newsletter - July 16th

1y ago, source: Forbes

Histogen Inc (HSTO) – The regenerative medicine company is a Top Short for next week with our AI rated them a D in our Technicals and Quality Value factors. Their earnings per share in the 12 ...

Welcome to Inc.'s Directory of B2B Excellence

2mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

11mon ago, source: Hosted on MSN

Rain Oncology Inc. (NASDAQ: RAIN) shares dipped 87.3% to $1.2700 after the company’s Phase 3 MANTRA trial of milademetan in dedifferentiated liposarcoma, did not meet its primary endpoint of ...

Evelo Biosciences, Inc. (EVLO)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket

1y ago, source: Hosted on MSN

Virgin Orbit Holdings, Inc. (NASDAQ: VORB) fell 22.1% to $0.5502 in pre-market trading. Virgin Orbit shares dipped 30% on Thursday after the company announced a company-wide operational pause in ...

Plus Therapeutics, Inc. (PSTV)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

CPH:BE Historical Data

6mon ago, source: Nasdaq

Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the ...

Etsy Inc.

3d ago, source: Wall Street Journal

1 Day ETSY -0.46% DJIA 0.67% S&P 500 0.87% Retail/Wholesale 0.37% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...

‘Food, Inc. 2’ Review: A Second Course

15d ago, source: The New York Times

Share full article “Food, Inc. 2,” directed by Robert Kenner and Melissa Robledo, begins by describing how the last few years have shown the risks of letting a handful of mega-suppliers ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...